Dabrafenib
Term · Oncology and biomedicine · MLC-T-ONC-012894
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
| Identifier | MLC-T-ONC-012894 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | BRAF inhibitor GSK2118436 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012894",
"term": "Dabrafenib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.",
"synonyms": [
"BRAF inhibitor GSK2118436"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dabrafenib/"
}
Record 5,644 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.